On Tuesday, the US Food and Drug Administration (FDA) approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for people 18 to 59 who are more vulnerable to the virus. Pfizer’s ...
Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...
Results that may be inaccessible to you are currently showing.